Open AccessCost Effectiveness of Latest Recommendations for Group B Streptococci Screening in the United States
Author(s) -
Marvin Williams,
Emily Zantow,
Mark A. Turrentine
Publication year - 2020
Publication title -
obstetrics and gynecology (new york. 1953. online)/obstetrics and gynecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.664
H-Index - 220
eISSN - 1873-233X
pISSN - 0029-7844
DOI - 10.1097/aog.0000000000003649
Subject(s) - medicine , gestation , guideline , population , obstetrics , cohort , pregnancy , group b , cost effectiveness , pediatrics , quality adjusted life year , gynecology , environmental health , risk analysis (engineering) , genetics , pathology , biology
To evaluate whether group B streptococci (GBS) screening using the 2010 guideline (screening at 35 0/7-37 6/7 weeks of gestation) compared with the 2019 guideline (screening at 36 0/7-37 6/7 weeks of gestation with re-screening of women with GBS-negative results 5 weeks later) was more cost effective.